A randomised, double-blind, double dummy, multicentre study to evaluate the efficacy and safety of esomeprazole 40 mg given i.v. or orally o.d. for 1 week to subjects with erosive reflux esophagitis, followed by 3 weeks' open oral treatment with esomeprazole 40 mg o.d.

Study identifier:D9615L00005

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A randomised, double-blind, double dummy, multicentre study to evaluate the efficacy and safety of esomeprazole 40 mg given i.v. or orally o.d. for 1 week to subjects with erosive reflux esophagitis, followed by 3 weeks' open oral treatment with esomeprazole 40 mg o.d.

Medical condition

gastrointestinal diseases

Phase

N/A

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Mar 2005
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria